BAY-204（Cat No.:I043841）is a small molecule inhibitor being developed to target specific proteins involved in cancer cell growth and survival. It works by blocking key signaling pathways, thereby inhibiting tumor proliferation and inducing cell death in cancerous cells. Preclinical studies suggest that BAY-204 has potential effectiveness against various cancers, including solid tumors and hematologic malignancies. By selectively targeting cancer-related pathways, BAY-204 aims to minimize toxicity to healthy cells, making it a promising candidate for targeted cancer therapies. Research is ongoing to assess its safety, efficacy, and potential clinical applications in oncology.